ProCE Banner Activity

My Perspective on 3 Questions I Am Asked on BTK Inhibitors for CLL

Clinical Thought
In this commentary, Ian W. Flinn, MD, PhD, provides expert answers to frequently asked questions on the use of BTK inhibitors in the management of patients with CLL.

Released: November 16, 2020

Expiration: November 15, 2021

No longer available for credit.

Share

Faculty

Ian W. Flinn

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Faculty Disclosure

Primary Author

Ian W. Flinn, MD, PhD

Chief Scientific Officer
One Oncology and Tennessee Oncology
Nashville, Tennesse

Ian W. Flinn, MD, PhD, has disclosed that Sarah Cannon has received consulting fees from AstraZeneca, BeiGene, Curio, Gilead Sciences, Iksuda, Nurix, Pharmacyclics, Roche, and TG Therapeutics; has received funds for research support paid to his institution from AbbVie, Acerta, Agios, ArQule, AstraZeneca, BeiGene, Calithera, Celgene, Constellation, Curis, F. Hoffmann-La Roche, Forma, Forty Seven, Genentech, Gilead Sciences, IGM Biosciences, Incyte, Infinity, Janssen, Juno, Karyopharm, Kite, Loxo, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium, Triphase Research & Development, Unum, and Verastem.